Practice guidelines for prenatal and perinatal immunohematology, revisited
2001; Wiley; Volume: 41; Issue: 11 Linguagem: Inglês
10.1046/j.1537-2995.2001.41111445.x
ISSN1537-2995
Autores Tópico(s)Prenatal Screening and Diagnostics
ResumoTransfusionVolume 41, Issue 11 p. 1445-1452 Practice guidelines for prenatal and perinatal immunohematology, revisited W. John Judd, W. John Judd From the Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan.Search for more papers by this authorfor the Scientific Section Coordinating Committee of the AABB, for the Scientific Section Coordinating Committee of the AABB From the Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan.Search for more papers by this author W. John Judd, W. John Judd From the Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan.Search for more papers by this authorfor the Scientific Section Coordinating Committee of the AABB, for the Scientific Section Coordinating Committee of the AABB From the Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan.Search for more papers by this author First published: 24 November 2002 https://doi.org/10.1046/j.1537-2995.2001.41111445.xCitations: 82 Address reprint requests to: W. John Judd, FIBMS, MIBiol, Department of Pathology, UH-2G332, University of Michigan Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0054; e-mail: [email protected]. This document represents the opinions of the author and does not represent policy of the American Association of Blood Banks. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Judd WJ, Luban NLC, Ness PM, et al. Prenatal and perinatal immunohematology: recommendations for serologic management of the fetus, newborn infant, and obstetric patient. Transfusion 1990; 30: 175 – 83. 10.1046/j.1537-2995.1990.30290162907.x CASPubMedWeb of Science®Google Scholar 2 Queenan JT, Tomai TP, Ural SH, King JC. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management. Am J Obstet Gynecol 1993; 168: 1370 – 6. 10.1016/S0002-9378(11)90767-4 CASPubMedWeb of Science®Google Scholar 3 Prevention of hemolytic disease of the newborn due to anti-D. Association Bulletin 98-2. Bethesda: AABB, February 16, 1998. Google Scholar 4 Vengelen-Tyler V, Ed. . Technical manual. 13th ed. Bethesda: American Association of Blood Banks, 1999. Google Scholar 5 Menitove JE, Ed. . Standards for blood banks and transfusion services. 19th ed. Bethesda: American Association of Blood Banks, 1999. Google Scholar 6 Sebring ES, Polesky HF. Detection of fetal maternal hemorrhage in Rh immune globulin candidates. A rosetting technique using enzyme-treated Rh2Rh2 indicator erythrocytes. Transfusion 1982; 22: 468 – 71. 10.1046/j.1537-2995.1982.22683068604.x CASPubMedWeb of Science®Google Scholar 7 Butch SH, Judd WJ. Simplified protocol for screening Rh immune globulin candidates (abstract). Transfusion 1983; 23: 440. Web of Science®Google Scholar 8 Lubenko A, Contreras M, Habash J. Should anti-Rh immunoglobulin be given to D variant women? Br J Haematol 1989; 72: 429 – 33. 10.1111/j.1365-2141.1989.tb07727.x CASPubMedWeb of Science®Google Scholar 9 Wagner FF, Kasulke D, Kerowgan M, Flegel WA. Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in south-western Germany. Infusionsther Transfusionsmed 1995; 22: 285 – 90. CASPubMedWeb of Science®Google Scholar 10 Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunization during pregnancy: antenatal prophylaxis. CMAJ 1978; 118: 623 – 7. CASPubMedWeb of Science®Google Scholar 11 Clinical management for obstetricians-gynecologists. ACOG Practice Bulletin Number 4. Washington: American College of Obstetricians and Gynecologists, 1999. Google Scholar 12 Rothenberg JM, Weirermiller B, Dirig K, et al. Is a third-trimester antibody screen in Rh+ women necessary? Am J Manag Care 1999; 5: 1145 – 50. CASPubMedWeb of Science®Google Scholar 13 Heddle NM, Klama L, Frassetto R, et al. A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993; 23: 217 – 20. 10.1046/j.1537-2995.1993.33393174447.x Web of Science®Google Scholar 14 Shulman IA, Calderon C, Nelson JM, Nakayama R. The routine use of Rh-negative reagent red cells for the identification of anti-D and the detection of non-D red cell antibodies. Transfusion 1994; 34: 666 – 70. 10.1046/j.1537-2995.1994.34894353460.x CASPubMedWeb of Science®Google Scholar 15 Reid ME, Chandrasekaran V, Sausais L, et al. Disappearance of antibodies to Cromer blood group system antigens during mid pregnancy. Vox Sang 1996; 71: 48 – 50. 10.1046/j.1423-0410.1996.7110048.x PubMedWeb of Science®Google Scholar 16 Smith ML, Beck ML. The immunoglobulin structure of human anti-M agglutinins. Transfusion 1979; 19: 472 – 4. 10.1046/j.1537-2995.1979.19479250186.x CASPubMedWeb of Science®Google Scholar 17 Reid ME, Lomas-Francis C. The blood group antigen FactsBook. San Diego: Academic Press, 1997: 32. Web of Science®Google Scholar 18 Bowman JM, Pollock JM. Amniotic fluid spectrophotometry and early delivery in the management of erythroblastosis fetalis. Pediatrics 1965; 35: 815 – 9. CASPubMedWeb of Science®Google Scholar 19 Weiner CP, Williamson RA, Wenstrom KD, et al. Management of fetal hemolytic disease by cordocentesis. I. Prediction of fetal anemia. Am J Obstet Gynecol 1991; 165: 546 – 53. 10.1016/0002-9378(91)90281-U PubMedWeb of Science®Google Scholar 20 Wade RV. Images, imagination and ideas: a perspective on the impact of ultrasonography on the practice of obstetrics and gynecology. Presidential address. Am J Obstet Gynecol 1999; 181: 235 – 9. 10.1016/S0002-9378(99)70541-7 CASPubMedWeb of Science®Google Scholar 21 Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342: 9 – 14. 10.1056/NEJM200001063420102 CASPubMedWeb of Science®Google Scholar 22 Queenan JT. Modern management of the Rh problem. 2nd ed. Hagerstown, MD: Harper and Row, 1977. Google Scholar 23 Freda VJ. The Rh problem in obstetrics and a new concept of its management using amniocentesis and spectrophotometric scanning of amniotic fluid. Am J Obstet Gynecol 1965; 92: 341 – 74. 10.1016/0002-9378(65)90391-1 CASPubMedWeb of Science®Google Scholar 24 Sazama K. Comprehensive transfusion medicine survey J-C, final critique. Chicago: College of American Pathologists, 1995. Google Scholar 25 Lapierre Y, Rigal D, Adam J, et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion 1990; 30: 109 – 13. 10.1046/j.1537-2995.1990.30290162894.x CASPubMedWeb of Science®Google Scholar 26 Spinnato JA. Hemolytic disease of the fetus: a plea for restraint. Obstet Gynecol 1992; 80: 873 – 7. CASPubMedWeb of Science®Google Scholar 27 Goodrick MJ, Hadley AG, Poole G. Haemolytic disease of the fetus and newborn due to anti-Fya and the potential clinical value of Duffy genotyping in pregnancies at risk. Transfus Med 1997; 7: 301 – 4. 10.1046/j.1365-3148.1997.d01-38.x CASPubMedWeb of Science®Google Scholar 28 Vaughan JI, Manning M, Warwick RM, et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998; 338: 798 – 803. 10.1056/NEJM199803193381204 CASPubMedWeb of Science®Google Scholar 29 Shirey RS, Mirabella DC, Lumadue JA, Ness PM. Differentiation of anti-D, -C, and -G: clinical relevance in alloimmunized pregnancies. Transfusion 1997; 37: 493 – 6. 10.1046/j.1537-2995.1997.37597293879.x CASPubMedWeb of Science®Google Scholar 30 Judd WJ. Methods in immunohematology. 2nd ed. Durham, NC: Montgomery Scientific Publications, 1994. Google Scholar 31 Van Dijk BA, Dooren MC, Overbeeke MA. Red cell antibodies in pregnancy: there is no ‘critical titre.’ Transfus Med 1995; 5: 199 – 202. 10.1111/j.1365-3148.1995.tb00228.x PubMedWeb of Science®Google Scholar 32 Engelfreit CP, Reesink HW, Bowman J, et al. Laboratory procedures for the prediction of the severity of haemolytic disease of the newborn. Vox Sang 1995; 69: 61 – 9. 10.1111/j.1423-0410.1995.tb00349.x PubMedGoogle Scholar 33 Lucas GF, Hadley AG, Nance SJ, Garratty G. Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test. Transfusion 1993; 33: 484 – 7. 10.1046/j.1537-2995.1993.33693296810.x CASPubMedWeb of Science®Google Scholar 34 Sacks DA, Nance SJ, Garratty G, et al. Monocyte monolayer assay as a predictor of severity of hemolytic disease of the fetus and newborn. Am J Perinatol 1993; 10: 428 – 31. 10.1055/s-2007-994623 PubMedWeb of Science®Google Scholar 35 Hadley AG, Wilkes A, Goodrick J, et al. The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn. Br J Obstet Gynaecol 1998; 105: 231 – 4. 10.1111/j.1471-0528.1998.tb10059.x CASPubMedWeb of Science®Google Scholar 36 Bowman JM. Hemolytic disease of the newborn. Vox Sang 1996; 70: 62 – 7. 10.1111/j.1423-0410.1996.tb01371.x Web of Science®Google Scholar 37 Oepkes D van Kemp IL, Simon MJG, et al. Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstetr Gynecol 2001; 184: 1015 – 20. 10.1067/mob.2001.112970 Web of Science®Google Scholar 38 Avent ND, Finning KM, Martin PG, Soothill PW. Prenatal determination of fetal blood group status. Vox Sang 2000; 78: 155 – 62. CASPubMedWeb of Science®Google Scholar 39 Van Den Veyver IB, Subramanian SB, Hudson KM, et al. Prenatal diagnosis of the RhD fetal blood type on amniotic fluid by polymerase chain reaction. Obstet Gynecol 1996; 87: 419 – 22. 10.1016/0029-7844(95)00443-2 CASPubMedWeb of Science®Google Scholar 40 Ness PM, Salamon JL. The failure of postinjection Rh immune globulin titers to detect large fetal-maternal hemorrhages. Am J Clin Pathol 1986; 85: 604 – 6. 10.1093/ajcp/85.5.604 CASPubMedWeb of Science®Google Scholar 41 Kleihauer E, Betke K. [Practical application of the detection of HbF-containing cells in fixed blood smears]. Internist 1960; 1: 292 – 6. CASPubMedGoogle Scholar 42 Lubenko A, Williams M, Johnson A, et al. Monitoring the clearance of fetal RhD-positive red cells in FMH following RhD immunoglobulin administration. Transfus Med 1999; 9: 331 – 5. 10.1046/j.1365-3148.1999.00217.x CASPubMedWeb of Science®Google Scholar 43 Riley JZ, Ness PM, Taddie SJ, et al. Detection and quantitation of fetal maternal hemorrhage utilizing an enzyme-linked antiglobulin test. Transfusion 1982; 22: 472 – 4. 10.1046/j.1537-2995.1982.22683068605.x CASPubMedWeb of Science®Google Scholar 44 Practice parameter: management of hyperbiliruinemaia in the healthy term newborn. American Academy of Pediatrics, Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia.Pediatrics 1994; 94: 558 – 65. PubMedGoogle Scholar 45 Joint Commission on Accreditation of Healthcare Organizations, Sentinel Event Alert. Issue 18: Kernicterus threatens healthy newborns. April 2001: (http://www.jcaho.org/edupub/sealert/sea18.html). Google Scholar Citing Literature Volume41, Issue11November 2001Pages 1445-1452 ReferencesRelatedInformation
Referência(s)